Roivant Sciences Ltd at Citi BioPharma Conference Transcript
Terrific. Well, delighted to introduce our next session with Roivant. I have the CEO with me, Matt Gline. I have Richard Pulik, the CFO and Investor Relations in the audience today.
So Roivant is a very different type of pharma company with a fairly unique business model, but one that so far has enjoyed some considerable success, both with your marketed agents, but also with 3 agents you have, and I'm just going to say, late-stage development, but that's a bit generous for the mid-late, early late stage...
You can call them late stage.
Questions & Answers
Yes, we can call them. So maybe just starting with the TL1A antagonist and obviously, starting with the Prometheus data, the Merck acquisition and then your data in UC, there's an extraordinary amount of interest in it. And the transaction from your
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
